CandorIQ Raises $4.8M Seed Round to Help Companies Take Control of People Spend
Whether it's identifying top performers at risk of churn or ensuring pay equity across teams, CandorIQ automates what used to take hours of manual work.
CandorIQ's AI capabilities are embedded across the platform, helping teams surface insights, flag potential risks, and automate complex workflows that would otherwise require days of manual effort. From automating compensation outliers to modeling headcount scenarios, the AI agents act as an always-on partner for HR and Finance teams navigating fast-moving organizational dynamics.
Staying aligned on compensation and headcount planning has long felt like a losing battle. Teams are forced to toggle between spreadsheets, siloed systems, and disconnected workflows, slowing decisions and introducing risk. Despite people spend accounting for 70% of employer costs according to the U.S. Bureau of Labor Statistics, it's still one of the least strategically managed. Compensation workflows are often fragmented across teams and tools, with no unified system of record.
That challenge has only intensified in recent years, as companies swing between aggressive hiring and cost-cutting and raise the stakes for every comp and headcount decision. CandorIQ replaces that complexity with a collaborative, AI-powered platform that unifies compensation, headcount planning, benchmarking, and equity strategy. The result is not just operational efficiency, but a more strategic, transparent approach to workforce planning that aligns leadership around clear, data-backed decisions.
'Workforce planning shouldn't feel like a quarterly fire drill,' said Haris Ikram, Co-Founder and CEO of CandorIQ. 'We built CandorIQ to help companies make smarter, faster people decisions by putting HR, Finance, and leadership on the same page, with the same data.'
Organizations like Newfront, SmartRecruiters, Monte Carlo, and Fleetio rely on CandorIQ to support high-impact initiatives from compensation reviews to dynamic scenario planning. Its AI agents also help teams surface critical insights faster, reduce manual analysis, and proactively guide decisions before issues escalate.
The platform has helped customers accelerate merit cycles by 2.5x, cut hiring timelines in half, and reduce employee churn by up to 25%—delivering average annual savings of more than $500,000. Whether it's identifying top performers at risk of churn or ensuring pay equity across teams, CandorIQ automates what used to take hours of manual work.
CandorIQ also integrates with more than 100 HR and Finance tools, pulling fragmented data into a centralized decision-making layer. Instead of relying on consultants or cobbling together insights from disconnected systems, teams get real-time answers they can trust, whether they're building budgets, structuring offers, or navigating a merit cycle.
'Compensation is both one of the biggest cost centers inside a company and one of the least well-managed,' said Shruti Gandhi, partner at Array Ventures. 'CandorIQ is bringing clarity, automation, and accountability to a space that's been held together by spreadsheets for too long.'
As companies scale, so do the risks of fragmented planning and inconsistent decision-making. CandorIQ helps eliminate these blind spots by aligning HR and Finance around a shared system of record. Its platform enables leaders to act with greater confidence and use data to guide every compensation and workforce strategy decision, from offers to organizational design.
For more information about CandorIQ or to request a demo, visit our website.
About CandorIQ
CandorIQ is an AI-powered collaborative platform for compensation and headcount planning. By unifying internal data and global benchmarks into a single system, CandorIQ helps HR, Finance, and leadership teams make faster, smarter people decisions. CandorIQ is trusted by leading organizations across industries and was founded in 2023 with backing from Array Ventures, Y Combinator, CRV, and Switch Ventures. Learn more at www.candoriq.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
Introducing Cambridge Forum 2025: Tech for Good
CAMBRIDGE, England--(BUSINESS WIRE)-- Cambridge Forum 2025, themed 'Tech for Good', is set to bring together global technology leaders, development innovators, policymakers, entrepreneurs, and academics in Cambridge this September. This two-day event discusses technology as a force for inclusive empowerment and positive social impact. Our Vision: From Underserved to Unstoppable At Cambridge Forum, we believe that technology can transform lives—especially in underserved communities. Rooted in Cambridge's academic and innovation ecosystem, we will foster collaboration across technology, development, academia, policy, and the private sector to bring solutions to the world's pressing challenges. Taking place in the historic city of Cambridge—a global hub for intellectual discovery—the Forum aims to be a permanent platform for inclusive collaboration across disciplines, sectors, and geographies. 'We believe the world's toughest challenges can't be solved in silos. Cambridge Forum offers a shared space to design, build, and scale innovation for good,' said Dr. Ehab Shanti, Founding Director of Cambridge Forum. 'AI undoubtedly presents enormous derivative challenges, but it also creates significant opportunities. Cambridge Forum will explore both,' he added. Cambridge Forum 2025 will feature a high-impact line-up of world-class speakers and changemakers, including: Marty Neumeier – Highly influential American author, designer, and business advisor focused on the intersection of design, branding, and innovation will deliver a session on 'Goodness as Corporate DNA'. Jaideep Prabhu – Co-author of Jugaad Innovation: Think Frugal, Be Flexible, will deliver a session on" Frugal Innovation: Leveraging Digital Public Infrastructure for Inclusive Artificial Intelligence'. Dr. Gareth Corbett, Chief Medical Officer, Onion AI will discuss, 'Tech for Good, The Case of AI and Health'. Henning Grosse Ruse Khan - Professor of Law at the University of Cambridge will discuss, 'Can We Regulate AI to Prevent Harm?'. Why It Matters In a time of global complexity and rapid technological advancement, we aim to ensure no one is left behind. By fostering cross-sector collaboration and offering practical tools, Cambridge Forum helps turn big ideas into real-world solutions to address the world's most pressing issues. About Cambridge Forum Cambridge Forum is a training and knowledge-sharing event that provides participants with a unique opportunity to learn. Through practical training and real-world applications, we will discuss how to harness advanced technology in AI and Insurtech to address the world's most pressing challenges and serve underserved communities.
Business Wire
an hour ago
- Business Wire
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Anocca AB ('Anocca' or the 'Company'), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca's gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca's preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands. Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.' Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.' SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors. ENDS About Anocca Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product. More information about the clinical trial can be found at the EU's clinical trials website. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166 2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w
Yahoo
2 hours ago
- Yahoo
EZVIZ Reshapes Front Door Security with the Y3000FVP Plus, the Flagship Smart Lock to Integrate Facial and Palm Vein Recognition for Ultimate Protection and Convenience
DUBAI, United Arab Emirates, August 18, 2025--(BUSINESS WIRE)--EZVIZ, a global leader in smart home security, proudly announces the launch of its latest flagship innovation, the Y3000FVP Plus, a premium smart lock that combines facial recognition and palm vein recognition for unbeatable security and convenience. With next-generation AI capabilities, multiple unlocking methods, and an enhanced safety design, the Y3000FVP Plus promises to provide homeowners with an unparalleled level of protection, ease of access, and peace of mind. "We're giving homeowners a smarter and more reliable way to protect their home," said Grant Chen, Vice President of EZVIZ. "With the Y3000FVP Plus, EZVIZ leverages the most cutting-edge technology to protect what matters most." Marking its hot debut in the Middle East, EZVIZ has captured the locally upscaling demand for elegant, intelligent home solutions, while witnessing the lack of a hassle-free user experience. Combining product quality with exceptional customer support, EZVIZ has developed its network of professional installers and related services, so the overall user journey can go as smoothly as possible from purchase, installation, and after-sales care. At the heart of the Y3000FVP Plus are its two industry-leading unlocking methods. This smart lock uses localized 3D data processing to guarantee only live, real-time faces are detected, even adapting to various lighting conditions. It reliably identifies individuals between 1.2m and 2m, unaffected by hairstyle, makeup, or glasses. For added convenience, especially in situations where users might be wearing a mask or carrying items, palm vein recognition provides a secure, forgery-resistant alternative. Both methods are powered by a 12nm AI chip and dual-core CPU, ensuring swift, accurate recognition. Furthermore, there are multiple user-friendly access options, from fingerprint scanning for quick entry, to passcodes for guest access, and even app-based remote unlocking for those constantly on the move. Beyond convenience, the Y3000FVP Plus prioritizes front door security. Equipped with a 1080p camera featuring ultra-wide viewing and night vision, the lock ensures clear monitoring at any time of the day or night. Users receive real-time alerts when movement is detected and can review recorded events. For enhanced protection, the lock is fortified with anti-theft features, such as an automatic siren to deter tampering, a C-grade cylinder to block unauthorized access, and long passcodes to safeguard against guessing attempts. View source version on Contacts Charlene Lilixiaolan15@ Sign in to access your portfolio
